These include being women, thyroid disease, menopausal or perimenopausal, and rapid weight loss
In the main Phase III trial, people lost about 15% of their visceral fat over 26 weeks on 2 mg a day
Both cagrilintide and retatrutide have specific contraindications and populations requiring special consideration [19]: Absolute Contraindications: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Previous severe allergic reaction to either compound Pregnancy or breastfeeding (insufficient safety data) Relative Contraindications Requiring Careful Evaluation: History of pancreatitis Severe gastroparesis or GI motility disorders Active gallbladder disease Severe renal impairment History of eating disorders Concurrent use of other appetite suppressants The cagrilintide dosage with retatrutide combination would carry all contraindications for both compounds, plus additional caution due to unknown interactions
However, the clinical trial data suggests this is primarily related to rapid weight loss rather than the drug itself
Tirzepatide typically starts at a lower absolute dose (2.5 mg) even if you were on a higher Ozempic dose, because tirzepatide's dual-receptor mechanism is more potent
By using a dual colour labelling kit, it is possible to compare samples from two different conditions
